Home › Quitting Smoking (Tobacco Use Disorder) › NCT05587361
Beta-Adrenergic Modulation of Drug Cue Reactivity
Beta-Adrenergic Modulation of Drug Cue Reactivity: Neural and Behavioral Mechanisms
Who can join
Ages 21 to 60 · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: 1. Generally healthy 2. Age 21-60 3. Right-handed using a three-item scale 4. Daily smoker of ≥ 5 cigarettes/day delivering 0.5 mg nicotine (FTC) 5. Smoking regularly for ≥ 1 year, with stable smoking for the past 6 months 6. Afternoon expired Carbon Monoxide (CO) concentration ≥ 6 ppm and/or morning urinary cotinine \>100 ng/ml 7. Must identity at least 4 different smoking locations used in a typical week 8. Able to read and understand English Exclusion Criteria: 1. Inability to attend all required sessions 2. Significant health problems that would preclude active participation 3. Presence of conditions that would make MRI unsafe (e.g. pacemaker) or (e.g. weight and body shape) 4. Current use of psychoactive medications/drugs as indicated by self-report or urine screen 5. Positive breath alcohol concentration 6. Pregnant, breastfeeding, or planning to become pregnant during the course of the study (females) 7. Problems with vision that cannot be corrected with contacts or glasses 8. Current regular use of smokeless tobacco, smoking cessation medications, or other nicotine containing products (e.g. electronic cigarettes) 9. Current use of beta-adrenergic medications (e.g. beta-blockers) or other blood pressure medications 10. Systolic blood pressure \< 90 mmHg or diastolic blood pressure \< 60 mmHg (sitting or standing) 11. Abnormal EKG 12. Presence of severe anemia 13. Presence of electrolyte imbalance that could impact blood pressure 14. Presence of any other contraindications for propranolol or nicotine patch (e.g. cardiovascular disease, bronchial asthma, prior allergic reactions, diabetes)
About the study
This study is designed to investigate the effects of a beta-adrenergic antagonist (Propranolol; 40 mg IR) and nicotine patch (14 mg) administered alone and in combination on neurobiological and behavioral responses to smoking cues in ongoing cigarette smokers. This is a basic experimental study in humans and participants will not take these medications for an extended period or make a cessation attempt as part of their involvement in this research project.
What is being tested
- Propranolol (drug)
- Nicotine Patch (drug)
- Placebo Propranolol (drug)
- Placebo Patch (drug)
Sponsor: University of Oklahoma · Participants: 80 · Started: Nov 26, 2024
Contact the study team
- Jason A Oliver, PhD · Phone: 405-271-8001
Official record on ClinicalTrials.gov — NCT05587361
Locations in the U.S.
| Oklahoma | Hardesty Center for Clinical Research and Neuroscience, Tulsa |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.